Hyperkalemia in patients with Heart Failure (HF) has been associated with adverse outcomes including cardiac arrhythmia and death. In cases of hyperkalemia (>5 mEq/L), paralysis, arrhythmias, and death are more likely to occur, especially when potassium levels exceed 6.5 mEq/L. HF patients are an increased risk of developing hyperkalemia because of the use of certain medications, especially angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), aldosterone receptor antagonists (ARAs), and direct renin inhibitors (DRIs). Data has shown that many practitioners discontinue treatment with ACEi and ARBS when a patient develop hyperkalemia, particularly in those individuals with concurrent kidney disease. In addition, the 2017 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for HF stresses the importance of managing hyperkalemia, however, these recommendations do not include guidance on the use of newly approved potassium binders for the management of hyperkalemia in HF. The program: Evidence-Based Strategies for the Prevention and Management of Hyperkalemia, is designed to improve practitioner knowledge of the prevention and management of hyperkalemia in patients prescribed renin-angiotensin-aldosterone system (RAAS) inhibitors and implement evidence-based recommendations for the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and the prevention and management of hyperkalemia in heart failure patients.